Improved heart failure protection by FK664, a novel positive inotropic agent, in dog heart-lung preparations.
The effects of FK664, a novel positive inotropic agent, and enoximone on pentobarbital-induced heart failure were compared in dog heart-lung preparations. Both FK664 and enoximone improved the cardiac function curve in a dose-dependent manner and restored it to the control level at drug concentrations of 1 microgram/ml and 10 micrograms/ml, respectively. Therefore, the cardiotonic potency of FK664 appears to be 10 times that of enoximone. These agents were almost equal in force-rate separation of cardiac effect. Neither of the agents produced arrhythmia at any dose tested. These results suggest that FK664 may be a potent cardiotonic agent for the treatment of heart failure.
Sudo
Y
Y
Department of Pharmacology, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Takai
M
M
Esumi
K
K
D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D017335:Enoximone; D005112:Extracorporeal Circulation; D006321:Heart / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D007093:Imidazoles / Q000627:therapeutic use; D008168:Lung / Q000187:drug effects / Q000502:physiology; D011744:Pyrimidinones / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D007093:Imidazoles; D011744:Pyrimidinones; C062761:FK 664; D017335:Enoximone